1
|
Wang M, Wang L, Xu W, Chu Z, Wang H, Lu J, Xue Z, Wang Y. NeuroPep 2.0: An Updated Database Dedicated to Neuropeptide and Its Receptor Annotations. J Mol Biol 2024; 436:168416. [PMID: 38143020 DOI: 10.1016/j.jmb.2023.168416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2023] [Accepted: 12/19/2023] [Indexed: 12/26/2023]
Abstract
Neuropeptides not only work through nervous system but some of them also work peripherally to regulate numerous physiological processes. They are important in regulation of numerous physiological processes including growth, reproduction, social behavior, inflammation, fluid homeostasis, cardiovascular function, and energy homeostasis. The various roles of neuropeptides make them promising candidates for prospective therapeutics of different diseases. Currently, NeuroPep has been updated to version 2.0, it now holds 11,417 unique neuropeptide entries, which is nearly double of the first version of NeuroPep. When available, we collected information about the receptor for each neuropeptide entry and predicted the 3D structures of those neuropeptides without known experimental structure using AlphaFold2 or APPTEST according to the peptide sequence length. In addition, DeepNeuropePred and NeuroPred-PLM, two neuropeptide prediction tools developed by us recently, were also integrated into NeuroPep 2.0 to help to facilitate the identification of new neuropeptides. NeuroPep 2.0 is freely accessible at https://isyslab.info/NeuroPepV2/.
Collapse
Affiliation(s)
- Mingxia Wang
- Institute of Medical Artificial Intelligence, Binzhou Medical University, Yantai, Shandong 264003, China
| | - Lei Wang
- School of Software Engineering, Huazhong University of Science and Technology, Wuhan, Hubei 430074, China
| | - Wei Xu
- Institute of Medical Artificial Intelligence, Binzhou Medical University, Yantai, Shandong 264003, China
| | - Ziqiang Chu
- School of Software Engineering, Huazhong University of Science and Technology, Wuhan, Hubei 430074, China
| | - Hengzhi Wang
- School of Software Engineering, Huazhong University of Science and Technology, Wuhan, Hubei 430074, China
| | - Jingxiang Lu
- Institute of Medical Artificial Intelligence, Binzhou Medical University, Yantai, Shandong 264003, China
| | - Zhidong Xue
- Institute of Medical Artificial Intelligence, Binzhou Medical University, Yantai, Shandong 264003, China; School of Software Engineering, Huazhong University of Science and Technology, Wuhan, Hubei 430074, China
| | - Yan Wang
- Institute of Medical Artificial Intelligence, Binzhou Medical University, Yantai, Shandong 264003, China; School of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, Hubei 430074, China.
| |
Collapse
|
2
|
Chen Y, Wu L, Liu H, Li Z, Li L, Wu X, Lei Q, Yin A, Tong J, Liu K, Guan X, Zeng C, Zhang H, Wan Y, Huang X, Huang P, Yang Q, Zhou X, Niu J. Third-Trimester Maternal Serum Chemerin and Hypertension After Preeclampsia: A Prospective Cohort Study. J Am Heart Assoc 2023; 12:e027930. [PMID: 36847060 PMCID: PMC10111437 DOI: 10.1161/jaha.122.027930] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/01/2023]
Abstract
Background Limited data are available for postpartum hypertension prediction after preeclampsia. Methods and Results We examined the association between maternal serum chemerin levels in patients with preeclampsia and blood pressure (BP) levels after delivery in a prospective birth cohort of 15 041 singleton pregnant women. A total of 310 cases among 322 patients with preeclampsia (follow-up rate, 96.3%) were followed up during a mean 2.8 years after delivery. Compared with matched uncomplicated controls (n=310), serum chemerin measured at ≈35 gestational weeks was significantly increased in preeclampsia (171.8±49.2 versus 140.2±53.5 ng/mL; P<0.01) and positively correlated with the occurrence of postpartum hypertension, defined as either BP ≥130/80 mm Hg (per 1-SD increase: odds ratio [OR], 4.01 [95% CI, 2.77-5.81]) or as BP ≥140/90 mm Hg (per 1-SD increase: OR, 1.70 [95% CI, 1.28-2.25]) in patients with preeclampsia. The addition of chemerin levels improved the predictive performance of the clinical variable-derived prediction models for postpartum hypertension (for BP ≥130/80 mm Hg: area under the curve, 0.903 [95% CI, 0.869-0.937], Δ area under the curve, 0.070, P<0.001; for BP ≥140/90 mm Hg: area under the curve, 0.852 [95% CI, 0.803-0.902], Δ area under the curve, 0.030, P=0.002). The decision curve analysis revealed a net benefit of the chemerin-based prediction model for postpartum BP ≥130/80 mm Hg. Conclusions This study provides the first evidence supporting the independent predictive role of third-trimester maternal chemerin levels for postpartum hypertension after preeclampsia. Future study is warranted for external validation of this finding.
Collapse
Affiliation(s)
- Yixuan Chen
- Department of Obstetrics Shenzhen Maternity and Child Healthcare Hospital Shenzhen Guangdong China.,The First School of Clinical Medicine Southern Medical University Shenzhen Guangdong China
| | - Linlin Wu
- Department of Obstetrics and Gynecology, the Eighth Affiliated Hospital Sun Yat-sen University Shenzhen Guangdong China
| | - Hangkuan Liu
- Department of Cardiology Tianjin Medical University General Hospital Tianjin China
| | - Ziping Li
- Department of Cardiology Tianjin Medical University General Hospital Tianjin China
| | - Linjie Li
- Department of Cardiology Tianjin Medical University General Hospital Tianjin China
| | - Xiaoxia Wu
- Department of Obstetrics Shenzhen Maternity and Child Healthcare Hospital Shenzhen Guangdong China
| | - Qiong Lei
- Department of Obstetrics and Gynecology, the Eighth Affiliated Hospital Sun Yat-sen University Shenzhen Guangdong China
| | - Aiqi Yin
- Department of Obstetrics Shenzhen Maternity and Child Healthcare Hospital Shenzhen Guangdong China.,The First School of Clinical Medicine Southern Medical University Shenzhen Guangdong China
| | - Jianing Tong
- Department of Obstetrics and Gynecology, the Eighth Affiliated Hospital Sun Yat-sen University Shenzhen Guangdong China
| | - Kan Liu
- Department of Obstetrics Shenzhen Maternity and Child Healthcare Hospital Shenzhen Guangdong China.,The First School of Clinical Medicine Southern Medical University Shenzhen Guangdong China
| | - Xiaonian Guan
- Department of Obstetrics Shenzhen Maternity and Child Healthcare Hospital Shenzhen Guangdong China.,The First School of Clinical Medicine Southern Medical University Shenzhen Guangdong China
| | - Cuiping Zeng
- Department of Obstetrics and Gynecology, the Eighth Affiliated Hospital Sun Yat-sen University Shenzhen Guangdong China
| | - Huafan Zhang
- Department of Obstetrics Shenzhen Maternity and Child Healthcare Hospital Shenzhen Guangdong China.,The First School of Clinical Medicine Southern Medical University Shenzhen Guangdong China
| | - Yanmei Wan
- Department of Obstetrics Shenzhen Maternity and Child Healthcare Hospital Shenzhen Guangdong China.,The First School of Clinical Medicine Southern Medical University Shenzhen Guangdong China
| | - Xuna Huang
- Department of Obstetrics Shenzhen Maternity and Child Healthcare Hospital Shenzhen Guangdong China.,The First School of Clinical Medicine Southern Medical University Shenzhen Guangdong China
| | - Pingping Huang
- Department of Obstetrics and Gynecology, the Eighth Affiliated Hospital Sun Yat-sen University Shenzhen Guangdong China
| | - Qing Yang
- Department of Cardiology Tianjin Medical University General Hospital Tianjin China
| | - Xin Zhou
- Department of Cardiology Tianjin Medical University General Hospital Tianjin China
| | - Jianmin Niu
- Department of Obstetrics Shenzhen Maternity and Child Healthcare Hospital Shenzhen Guangdong China.,The First School of Clinical Medicine Southern Medical University Shenzhen Guangdong China
| |
Collapse
|
3
|
Yang X, Liu L, Xiong X, Zhang Y, Liu Y, Li H, Yao K, Wang J. Effects of Bushen-Jiangya granules on blood pressure and pharmacogenomic evaluation in low-to-medium-risk hypertensive patients: study protocol for a randomized double-blind controlled trial. Trials 2022; 23:37. [PMID: 35033168 PMCID: PMC8760657 DOI: 10.1186/s13063-022-05999-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2021] [Accepted: 01/03/2022] [Indexed: 11/25/2022] Open
Abstract
INTRODUCTION Hypertension is one of the most important risk factors for cardiovascular disease, and its control rates remain low worldwide. The most effective strategy is that patients with hypertension should be diagnosed and treated early. Preliminary studies showed that the Bushen Jiangya granule (BSJY) could suppress ventricular hypertrophy and inflammatory responses, lower blood pressure, and protect the target organs of hypertension. We designed a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of BSJY in patients with low-to-medium risk hypertension. METHODS AND ANALYSIS This trial is a one-center, randomized, double-blind, placebo-controlled study. A total of 260 participants will be randomized in a 1:1 ratio to an experimental group (BSJY plus amlodipine) and a control group (placebo plus amlodipine). The trial cycle will last 8 weeks. The primary outcome is the change in 24-h average systolic and diastolic blood pressure. The secondary outcomes include heart rate variability, pharmacogenomic evaluation, improvement in TCM syndrome, and serum pro-inflammatory/anti-inflammatory cytokines between the two groups. The safety of medication will also be evaluated. All the data will be recorded in electronic case report forms and analyzed by SPSS V.22.0. ETHICS AND DISSEMINATION This study has been approved by the Research Ethics Committee of Guang'anmen Hospital, China Academy of Chinese Medical Sciences in Beijing, China (No. 2019-186-KY-01). The participants are volunteers, understand the process of this trial, and sign an informed consent. The results of this study will be disseminated to the public through peer-reviewed journals and academic conferences. DISCUSSION We hypothesize that patients with low-to-medium-risk hypertension will benefit from BSJY. If successful, this study will provide evidence-based recommendations for clinicians. TRIAL REGISTRATION Chinese Clinical Trial Registry ChiMCTR1900002876. Registered in November 2019.
Collapse
Affiliation(s)
- Xiaochen Yang
- Department of Health Care, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
- Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
| | - Lanping Liu
- Department of Health Care, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Xingjiang Xiong
- Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Yun Zhang
- Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Yongmei Liu
- Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Hongzheng Li
- Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Kuiwu Yao
- Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Jie Wang
- Department of Health Care, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| |
Collapse
|
4
|
Tran K, Sainsily X, Côté J, Coquerel D, Couvineau P, Saibi S, Haroune L, Besserer-Offroy É, Flynn-Robitaille J, Resua Rojas M, Murza A, Longpré JM, Auger-Messier M, Lesur O, Bouvier M, Marsault É, Boudreault PL, Sarret P. Size-Reduced Macrocyclic Analogues of [Pyr 1]-apelin-13 Showing Negative Gα 12 Bias Still Produce Prolonged Cardiac Effects. J Med Chem 2022; 65:531-551. [PMID: 34982553 DOI: 10.1021/acs.jmedchem.1c01708] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
We previously reported a series of macrocyclic analogues of [Pyr1]-apelin-13 (Ape13) with increased plasma stability and potent APJ agonist properties. Based on the most promising compound in this series, we synthesized and then evaluated novel macrocyclic compounds of Ape13 to identify agonists with specific pharmacological profiles. These efforts led to the development of analogues 39 and 40, which possess reduced molecular weight (MW 1020 Da vs Ape13, 1534 Da). Interestingly, compound 39 (Ki 0.6 nM), which does not activate the Gα12 signaling pathway while maintaining potency and efficacy similar to Ape13 to activate Gαi1 (EC50 0.8 nM) and β-arrestin2 recruitment (EC50 31 nM), still exerts cardiac actions. In addition, analogue 40 (Ki 5.6 nM), exhibiting a favorable Gα12-biased signaling and an increased in vivo half-life (t1/2 3.7 h vs <1 min of Ape13), produces a sustained cardiac response up to 6 h after a single subcutaneous bolus injection.
Collapse
Affiliation(s)
- Kien Tran
- Département de Pharmacologie-Physiologie, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke J1H 5N4, Québec, Canada.,Institut de Pharmacologie de Sherbrooke, Sherbrooke J1H 5N4, Québec, Canada
| | - Xavier Sainsily
- Département de Pharmacologie-Physiologie, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke J1H 5N4, Québec, Canada.,Institut de Pharmacologie de Sherbrooke, Sherbrooke J1H 5N4, Québec, Canada
| | - Jérôme Côté
- Département de Pharmacologie-Physiologie, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke J1H 5N4, Québec, Canada.,Institut de Pharmacologie de Sherbrooke, Sherbrooke J1H 5N4, Québec, Canada
| | - David Coquerel
- Institut de Pharmacologie de Sherbrooke, Sherbrooke J1H 5N4, Québec, Canada.,Département de Médecine, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke J1H 5N4, Québec, Canada
| | - Pierre Couvineau
- Institut de Recherche en Immunologie et en Cancérologie (IRIC), Université de Montréal, Montreal H3T 1J4, Québec, Canada
| | - Sabrina Saibi
- Institut de Pharmacologie de Sherbrooke, Sherbrooke J1H 5N4, Québec, Canada
| | - Lounès Haroune
- Institut de Pharmacologie de Sherbrooke, Sherbrooke J1H 5N4, Québec, Canada
| | - Élie Besserer-Offroy
- Département de Pharmacologie-Physiologie, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke J1H 5N4, Québec, Canada.,Institut de Pharmacologie de Sherbrooke, Sherbrooke J1H 5N4, Québec, Canada.,Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, California 90095, United States
| | | | - Martin Resua Rojas
- Département de Pharmacologie-Physiologie, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke J1H 5N4, Québec, Canada.,Institut de Pharmacologie de Sherbrooke, Sherbrooke J1H 5N4, Québec, Canada
| | - Alexandre Murza
- Département de Pharmacologie-Physiologie, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke J1H 5N4, Québec, Canada.,Institut de Pharmacologie de Sherbrooke, Sherbrooke J1H 5N4, Québec, Canada
| | - Jean-Michel Longpré
- Département de Pharmacologie-Physiologie, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke J1H 5N4, Québec, Canada.,Institut de Pharmacologie de Sherbrooke, Sherbrooke J1H 5N4, Québec, Canada
| | - Mannix Auger-Messier
- Institut de Pharmacologie de Sherbrooke, Sherbrooke J1H 5N4, Québec, Canada.,Département de Médecine, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke J1H 5N4, Québec, Canada
| | - Olivier Lesur
- Institut de Pharmacologie de Sherbrooke, Sherbrooke J1H 5N4, Québec, Canada.,Département de Médecine, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke J1H 5N4, Québec, Canada
| | - Michel Bouvier
- Institut de Recherche en Immunologie et en Cancérologie (IRIC), Université de Montréal, Montreal H3T 1J4, Québec, Canada
| | - Éric Marsault
- Département de Pharmacologie-Physiologie, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke J1H 5N4, Québec, Canada.,Institut de Pharmacologie de Sherbrooke, Sherbrooke J1H 5N4, Québec, Canada
| | - Pierre-Luc Boudreault
- Département de Pharmacologie-Physiologie, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke J1H 5N4, Québec, Canada.,Institut de Pharmacologie de Sherbrooke, Sherbrooke J1H 5N4, Québec, Canada
| | - Philippe Sarret
- Département de Pharmacologie-Physiologie, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke J1H 5N4, Québec, Canada.,Institut de Pharmacologie de Sherbrooke, Sherbrooke J1H 5N4, Québec, Canada
| |
Collapse
|